Palbociclib, a cyclin-dependent kinases 4/6 (CDK4/6) inhibitor that induces G1 phase cell cycle arrest, is used in combination with aromatase inhibitors to treat metastatic luminal breast cancer, achieving an overall response rate of 42.1%. Here, CDK4 is linked to breast carcinoma.